1.Date of occurrence of the event:2022/07/07
2.Company name:Maxigen Biotech Inc
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:N/A
6.Countermeasures:N/A
7.Any other matters that need to be specified:
Maxigen Biotech Inc. (TWSE: 1783) today announced its net revenues
for June 2022.
On a consolidated basis, revenues for June 2022 were
approximately NT$ 62.372 million, an increase of 29.83 percent
over the same period in 2021.
Revenues for January through June 2022 totaled
NT$ 277.516 million, an increase of 19.58 percent compared to
the NT$ 232.083 million for the same period in 2021.
